271 related articles for article (PubMed ID: 33590519)
1. Health and Economic Outcomes Associated with Polio Vaccine Policy Options: 2019-2029.
Kalkowska DA; Thompson KM
Risk Anal; 2021 Feb; 41(2):364-375. PubMed ID: 33590519
[TBL] [Abstract][Full Text] [Related]
2. Cost analysis of post-polio certification immunization policies.
Sangrujee N; Cáceres VM; Cochi SL
Bull World Health Organ; 2004 Jan; 82(1):9-15. PubMed ID: 15106295
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of alternative polio immunization policies in South Africa.
Griffiths UK; Botham L; Schoub BD
Vaccine; 2006 Jul; 24(29-30):5670-8. PubMed ID: 16766096
[TBL] [Abstract][Full Text] [Related]
4. An economic analysis of poliovirus risk management policy options for 2013-2052.
Duintjer Tebbens RJ; Pallansch MA; Cochi SL; Wassilak SG; Thompson KM
BMC Infect Dis; 2015 Sep; 15():389. PubMed ID: 26404632
[TBL] [Abstract][Full Text] [Related]
5. Potential Future Use, Costs, and Value of Poliovirus Vaccines.
Thompson KM; Kalkowska DA
Risk Anal; 2021 Feb; 41(2):349-363. PubMed ID: 32645244
[TBL] [Abstract][Full Text] [Related]
6. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.
Ciapponi A; Bardach A; Rey Ares L; Glujovsky D; Cafferata ML; Cesaroni S; Bhatti A
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011260. PubMed ID: 31801180
[TBL] [Abstract][Full Text] [Related]
7. Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016.
Hampton LM; Farrell M; Ramirez-Gonzalez A; Menning L; Shendale S; Lewis I; Rubin J; Garon J; Harris J; Hyde T; Wassilak S; Patel M; Nandy R; Chang-Blanc D;
MMWR Morb Mortal Wkly Rep; 2016 Sep; 65(35):934-8. PubMed ID: 27606675
[TBL] [Abstract][Full Text] [Related]
8. Health economic analysis of vaccine options for the polio eradication endgame: 2022-2036.
Thompson KM; Kalkowska DA; Badizadegan K
Expert Rev Vaccines; 2022 Nov; 21(11):1667-1674. PubMed ID: 36154436
[TBL] [Abstract][Full Text] [Related]
9. Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV).
Thompson KM; Kalkowska DA
Expert Rev Vaccines; 2019 Jul; 18(7):725-736. PubMed ID: 31248293
[No Abstract] [Full Text] [Related]
10. An Updated Economic Analysis of the Global Polio Eradication Initiative.
Thompson KM; Kalkowska DA
Risk Anal; 2021 Feb; 41(2):393-406. PubMed ID: 33590521
[TBL] [Abstract][Full Text] [Related]
11. Eradicating polio: how the world's pediatricians can help stop this crippling illness forever.
Orenstein WA;
Pediatrics; 2015 Jan; 135(1):196-202. PubMed ID: 25548328
[TBL] [Abstract][Full Text] [Related]
12. The risks, costs, and benefits of possible future global policies for managing polioviruses.
Thompson KM; Tebbens RJ; Pallansch MA; Kew OM; Sutter RW; Aylward RB; Watkins M; Gary HE; Alexander J; Jafari H; Cochi SL
Am J Public Health; 2008 Jul; 98(7):1322-30. PubMed ID: 18511720
[TBL] [Abstract][Full Text] [Related]
13. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation.
Duintjer Tebbens RJ; Thompson KM
J Infect Dis; 2014 Nov; 210 Suppl 1():S485-97. PubMed ID: 25316871
[TBL] [Abstract][Full Text] [Related]
14. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes.
Thompson KM; Duintjer Tebbens RJ
BMC Infect Dis; 2015 Sep; 15():374. PubMed ID: 26381878
[TBL] [Abstract][Full Text] [Related]
15. Expected Implications of Globally Coordinated Cessation of Serotype 3 Oral Poliovirus Vaccine (OPV) Before Serotype 1 OPV.
Kalkowska DA; Thompson KM
Risk Anal; 2021 Feb; 41(2):312-319. PubMed ID: 32936466
[TBL] [Abstract][Full Text] [Related]
16. Introduction of Inactivated Poliovirus Vaccine and Switch from Trivalent to Bivalent Oral Poliovirus Vaccine - Worldwide, 2013-2016.
Immunization Systems Management Group of the Global Polio Eradication Initiative
MMWR Morb Mortal Wkly Rep; 2015 Jul; 64(25):699-702. PubMed ID: 26135591
[TBL] [Abstract][Full Text] [Related]
17. Poliovirus vaccines. Progress toward global poliomyelitis eradication and changing routine immunization recommendations in the United States.
Sutter RW; Prevots DR; Cochi SL
Pediatr Clin North Am; 2000 Apr; 47(2):287-308. PubMed ID: 10761505
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of New Primary Immunization Schedules With Inactivated Poliovirus Vaccine and Bivalent Oral Polio Vaccine for the Polio Endgame: A Review.
Bandyopadhyay AS; Modlin JF; Wenger J; Gast C
Clin Infect Dis; 2018 Oct; 67(suppl_1):S35-S41. PubMed ID: 30376081
[TBL] [Abstract][Full Text] [Related]
19. Assessing the stability of polio eradication after the withdrawal of oral polio vaccine.
Famulare M; Selinger C; McCarthy KA; Eckhoff PA; Chabot-Couture G
PLoS Biol; 2018 Apr; 16(4):e2002468. PubMed ID: 29702638
[TBL] [Abstract][Full Text] [Related]
20. Insights From Modeling Preventive Supplemental Immunization Activities as a Strategy to Eliminate Wild Poliovirus Transmission in Pakistan and Afghanistan.
Kalkowska DA; Thompson KM
Risk Anal; 2021 Feb; 41(2):266-272. PubMed ID: 32144841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
